What is the 13F Pro Quality Score for ERNA?

13F Pro ranks Ernexa Therapeutics Inc. (ERNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ERNA's current score at https://13fpro.ai/research/ERNA (free sign-up required for the full ranking).

Where does 13F Pro source ERNA data?

All Ernexa Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Ernexa Therapeutics Inc. files with the SEC under CIK 748592. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ERNA in?

Ernexa Therapeutics Inc. (ERNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ERNA research updated on 13F Pro?

ERNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ernexa Therapeutics Inc.(ERNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 748592 ERNA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $26.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ERNA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ernexa Therapeutics Inc. (ERNA), a Healthcare sector company. ERNA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $26.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Ernexa Therapeutics Inc. reports net income of $-5.5M, free cash flow of $-2.3M. Top institutional holders of ERNA by reported 13-F value include Bleichroeder, Dauntless Investment Group,, Corient Private Wealth, based on the most recent SEC filings. ERNA trades on the Nasdaq exchange and files with the SEC under CIK 748592. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ERNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ernexa Therapeutics Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-5.5M

Free Cash Flow

Q1 2026

$-2.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+755.9% YoY

$582.0KFY 2024

FY21 —FY22 $0.00FY23 $68.0KFY24 $582.0K

Net Income

-105.6% YoY

$-44.5MFY 2024

FY21 $-122.5MFY22 $-24.6MFY23 $-21.7MFY24 $-44.5M

Operating Income

+25.8% YoY

$-15.7MFY 2024

FY21 $-113.7MFY22 $-33.2MFY23 $-21.1MFY24 $-15.7M

EPS (Diluted)

-1100.0% YoY

$-48.96FY 2024

FY21 $-2.83FY22 $-8.06FY23 $-4.08FY24 $-48.96

Total Assets

-89.3% YoY

$5.3MFY 2024

FY21 $31.5MFY22 $22.3MFY23 $49.1MFY24 $5.3M

Total Debt

—FY 2024

FY21 —FY22 —FY23 —FY24 —

Op. Cash Flow

+22.4% YoY

$-15.8MFY 2024

FY21 $-23.5MFY22 $-21.0MFY23 $-20.4MFY24 $-15.8M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2017
Revenue	$582.0K +755.9%	$68.0K	$0.00	—	$19.8M -6.9%	$21.3M
Net Income	$-44.5M -105.6%	$-21.7M +11.8%	$-24.6M +79.9%	$-122.5M -5886.6%	$-2.0M -90.1%	$-1.1M
Operating Income	$-15.7M +25.8%	$-21.1M +36.4%	$-33.2M +70.8%	$-113.7M -6354.7%	$-1.8M -25.7%	$-1.4M
EPS (Diluted)	$-48.96 -1100.0%	$-4.08 +49.4%	$-8.06 -184.8%	$-2.83	—	—
Total Assets	$5.3M -89.3%	$49.1M +120.5%	$22.3M -29.3%	$31.5M +123.2%	$14.1M -14.8%	$16.6M
Total Debt	—	—	—	—	$2.7M -73.1%	$10.2M
Operating Cash Flow	$-15.8M +22.4%	$-20.4M +2.7%	$-21.0M +10.7%	$-23.5M -956.0%	$2.7M +399.8%	$549.0K

AI Insight: ERNA Financial Trends

Ernexa generates zero revenue across all reported periods, though cash burn has moderated significantly from Q3 2024's $27M net loss peak to $6M in Q1 2026.

• Net loss narrowed sharply from -$27M in Q3 2024 to -$1M in Q3 2025, suggesting meaningful reduction in non-operating charges.

• Operating cash outflow stabilized between -$1M and -$3M from Q4 2024 through Q1 2026, down from -$6M in Q3 2024.

• Equity turned positive at $7M in Q1 2026, recovering from deeply negative -$45M in Q3 2024.

• Revenue remains $0M across every reported quarter — the company has no commercial revenue base whatsoever.

⚠ Net loss spiked back to -$6M in Q1 2026 after three quarters of sub-$3M losses — worth monitoring for recurring volatility.

⚠ Total debt data is absent across all periods; undisclosed leverage is a meaningful blind spot for balance-sheet assessment.

⚠ Equity of $7M in Q1 2026 remains thin for a pre-revenue biotech; continued cash burn could rapidly erode this buffer.

AI Insight: ERNA Ratio Trends

Ernexa Therapeutics data is too sparse to assess a reliable trend, with only isolated ROE and ROA figures available.

• ROA was -47.6% in Q2 2024, the only available asset-return datapoint across the quarterly series.

• ROE deepened to -139.1% and ROA to -80.4% in Q3 2025, suggesting accelerating equity and asset erosion.

• TTM ROE stands at -166.0% through Q1 2026, the most negative equity-return reading in the available dataset.

⚠ Persistent data gaps across OpMargin, NPM, ROIC, and D/E make leverage and profitability trajectory impossible to assess.

⚠ ROE worsened from -139.1% in Q3 2025 to -166.0% TTM — monitor whether equity base is shrinking rapidly.

Get alerted when ERNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ernexa Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ERNA

Bleichroeder LP
$398.0K2,000,000 sh
Dauntless Investment Group, LLC
$121.9K612,443 sh
Corient Private Wealth LLC
$87.2K438,093 sh
GEODE CAPITAL MANAGEMENT, LLC
$48.6K244,446 sh
XTX Topco Ltd
$10.8K54,338 sh
Warberg Asset Management LLC
$10.1K50,000 sh
JANE STREET GROUP, LLC
$8.2K41,167 sh
CITADEL ADVISORS LLC
$6.6K33,076 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.3K26,504 sh
VANGUARD FIDUCIARY TRUST CO
$5.1K25,447 sh

Fund	Value	Shares
Bleichroeder LP	$398.0K	2,000,000
Dauntless Investment Group, LLC	$121.9K	612,443
Corient Private Wealth LLC	$87.2K	438,093
GEODE CAPITAL MANAGEMENT, LLC	$48.6K	244,446
XTX Topco Ltd	$10.8K	54,338
Warberg Asset Management LLC	$10.1K	50,000
JANE STREET GROUP, LLC	$8.2K	41,167
CITADEL ADVISORS LLC	$6.6K	33,076
VANGUARD CAPITAL MANAGEMENT LLC	$5.3K	26,504
VANGUARD FIDUCIARY TRUST CO	$5.1K	25,447

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ERNA on your watchlist

Track score changes the day Ernexa Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ERNA a good stock to buy?

13F Pro's AI-powered analysis of Ernexa Therapeutics Inc. (ERNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ERNA are available on the ERNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ERNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ERNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ernexa Therapeutics Inc.'s investment landscape.